5.06
+0.20%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Ocumension Therapeutics
Its shares trade on HKEX under the ticker 1477.HK. It has been listed since 10 July 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥936.9m and a net loss of CN¥185.0m. At that date it held total assets of CN¥4.77bn and shareholders' equity of CN¥4.29bn.
Ocumension Therapeutics engages in the identification, development, and commercialization of ophthalmic therapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2020-07-10. Its main products include OT-401 (YUTIQ), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-301 (NCX 470), OT-101 and OT-202, among others. The firm conducts its businesses in the domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 10 Jul 2020
- Employees
- 417
- Website
- ocumension.com ↗
Leadership
Pay as last reported
- Dr. Lian Yong ChenNon-Executive Chairman of the Board, since 2018
- Mr. Ye LiuChief Executive Officer, Executive Director, since 2018CN¥4.9m
- Mr. Tim RuanChief Financial Officer, Joint Company Secretary
- Dr. Zhaopeng HuChief Development Officer, Executive Director, since 2018CN¥2.1m
- Dr. DongHong ChenChief Medical Officer
- Mr. Qinglei ZuoChief Commercial Officer
- Ms. Tingchan ChenJoint Company Secretary
- Mr. Yanling CaoNon-Executive Director
- Dr. Wei LiNon-Executive Director, since 2018
- Mr. Yiran HuangNon-Executive Independent DirectorCN¥166,000
- Mr. Ting Yuk WuNon-Executive Independent DirectorCN¥415,000
- Mr. Zhenyu ZhangNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 75
- Environment
- 68
- Social
- 91
- Governance
- 65
- Direct emissions (scope 1)
- 577,458 t
- Energy emissions (scope 2)
- 207,278 t
- Value chain emissions (scope 3)
- 20,793,853 t
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Ocumension Therapeutics has 417 employees focused on ophthalmic therapies development.
- OT-401 (YUTIQ) is a key product in the ophthalmic market segment.
- The company's domestic market focus ensures strong local market presence.
Weaknesses
- Ocumension Therapeutics has only one headquarters city, Suzhou, Jiangsu.
- The company's business is limited to the domestic market, restricting international growth.
- Ocumension Therapeutics has no international market presence beyond China.
Opportunities
- OT-1001 (ZERVIATE) shows potential for expansion in the domestic ophthalmic market.
- OT-502 (DEXYCU) could gain market share in the domestic pharmaceutical sector.
- OT-301 (NCX 470) may attract interest in the domestic health care segment.
Threats
- Ocumension Therapeutics faces competition from other domestic pharmaceutical companies.
- The domestic market may have limited growth potential for ophthalmic therapies.
- Ocumension Therapeutics has no international market to mitigate domestic market risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.